{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:56Z","timestamp":1790949596268,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013183","name":"Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.intimp.2024.112872","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T17:21:12Z","timestamp":1723137672000},"page":"112872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-9354","authenticated-orcid":false,"given":"Jia-yan","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-liang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge-fan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-xing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112872_b0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.gastro.2021.10.017","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021","volume":"162","author":"Peery","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.112872_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.intimp.2024.112872_b0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1245\/s10434-015-4642-9","article-title":"Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection","volume":"23","author":"Spolverato","year":"2016","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2016.05.019","article-title":"Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models","volume":"223","author":"Doussot","year":"2016","journal-title":"J Am Coll Surg."},{"key":"10.1016\/j.intimp.2024.112872_b0025","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2024.112872_b0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.intimp.2024.112872_b0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000531820","article-title":"Multicenter phase ii trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD","volume":"13","author":"Ikeda","year":"2023","journal-title":"Liver Cancer."},{"key":"10.1016\/j.intimp.2024.112872_b0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","article-title":"Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol Int."},{"key":"10.1016\/j.intimp.2024.112872_b0045","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: A multicenter, phase iii randomized study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000362223","article-title":"Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience","volume":"59","author":"Ghiringhelli","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.intimp.2024.112872_b0055","first-page":"1853","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled","volume":"401","author":"Kelley","year":"2023","journal-title":"Phase 3 trial. Lancet."},{"key":"10.1016\/j.intimp.2024.112872_b0060","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.intimp.2024.112872_b0065","doi-asserted-by":"crossref","first-page":"114000","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.intimp.2024.112872_b0070","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of clear, a phase iii study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102386","article-title":"Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors","volume":"9","author":"Al-Toubah","year":"2024","journal-title":"ESMO Open."},{"key":"10.1016\/j.intimp.2024.112872_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110797","article-title":"The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma","volume":"132","author":"Wang","year":"2020","journal-title":"BioMed Pharmacother."},{"key":"10.1016\/j.intimp.2024.112872_b0085","article-title":"Overcoming resistance to immune checkpoint blockade in liver cancer - stronger together?","author":"Werner","year":"2024","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.intimp.2024.112872_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116659","article-title":"Unveiling the promise of PD1\/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma","volume":"175","author":"Chen","year":"2024","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.intimp.2024.112872_b0095","doi-asserted-by":"crossref","first-page":"20230079","DOI":"10.1259\/bjr.20230079","article-title":"Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study","volume":"96","author":"Ning","year":"2023","journal-title":"Br J Radiol."},{"key":"10.1016\/j.intimp.2024.112872_b0100","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/liv.15666","article-title":"Expression pattern of PD-1\/PD-L1 in primary liver cancer with clinical correlation","volume":"43","author":"Zeng","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.intimp.2024.112872_b0105","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2021.39.15_suppl.4094","article-title":"Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as frst-line treatment for advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"39","author":"Jian","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0110","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00330-019-06438-8","article-title":"A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation","volume":"30","author":"Ni","year":"2020","journal-title":"Eur Radiol."},{"key":"10.1016\/j.intimp.2024.112872_b0115","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1245\/s10434-024-15127-w","article-title":"Robotic versus open hepatic arterial infusion pump placement for unresectable intrahepatic cholangiocarcinoma","volume":"31","author":"Ten Haaft","year":"2024","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0120","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1245\/s10434-024-14971-0","article-title":"ASO author reflections: Laparoscopic surgery for intrahepatic cholangiocarcinoma-opportunities and challenges","volume":"31","author":"Dai","year":"2024","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0125","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2024.112872_b0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0140","doi-asserted-by":"crossref","first-page":"e4035","DOI":"10.1002\/cbf.4035","article-title":"Phosphatidylserine and Tyro3-axl-mertk receptor tyrosine kinase level detection in plasma and on plasma-derived extracellular vesicle surface in chronic lymphocytic leukemia","volume":"42","author":"Bay","year":"2024","journal-title":"Cell Biochem Funct."},{"key":"10.1016\/j.intimp.2024.112872_b0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12672-023-00631-4","article-title":"Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest","volume":"14","author":"Yan","year":"2023","journal-title":"Discov Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0150","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","article-title":"Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results","volume":"20","author":"Ueno","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2024.112872_b0155","doi-asserted-by":"crossref","first-page":"HEP49","DOI":"10.2217\/hep-2023-0006","article-title":"Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study","volume":"10","author":"Wang","year":"2023","journal-title":"Hepat Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical treatment of cholangiocarcinoma: an updated comprehensive review","volume":"27","author":"Elvevi","year":"2022","journal-title":"Ann Hepatol."},{"key":"10.1016\/j.intimp.2024.112872_b0165","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jhep.2024.02.008","article-title":"Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma","volume":"80","author":"Tomlinson","year":"2024","journal-title":"J Hepatol."},{"key":"10.1016\/j.intimp.2024.112872_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110344","article-title":"First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study","volume":"120","author":"Ye","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.112872_b0175","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/07853890.2022.2048416","article-title":"Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy","volume":"54","author":"Deng","year":"2022","journal-title":"Ann Med."},{"key":"10.1016\/j.intimp.2024.112872_b0180","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.intimp.2024.112872_b0185","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0190","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","article-title":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies","volume":"37","author":"Bang","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0195","doi-asserted-by":"crossref","first-page":"1235724","DOI":"10.3389\/fimmu.2023.1235724","article-title":"Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma","volume":"14","author":"Wei","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.112872_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.691380","article-title":"Systemic sequential therapy of cisgem, tislelizumab, and lenvatinib for advanced intrahepatic cholangiocarcinoma conversion therapy","volume":"11","author":"Ding","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.intimp.2024.112872_b0210","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","article-title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","volume":"31","author":"Lwin","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0215","article-title":"Lenvatinib combined with a PD-1 inhibitor as effective therapy for advanced intrahepatic cholangiocarcinoma","volume":"13","author":"Xie","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.intimp.2024.112872_b0220","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.500","article-title":"Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2024.112872_b0225","doi-asserted-by":"crossref","first-page":"1260191","DOI":"10.3389\/fimmu.2024.1260191","article-title":"Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924013936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924013936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:03:45Z","timestamp":1786363425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924013936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":44,"alternative-id":["S1567576924013936"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112872","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112872"}}